| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05324dcb1cf1d20b8023b975d4cda4ac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2230-0013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2002-825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-139
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2210-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-1352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2002-823
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G63-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L67-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-148
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-915 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-844
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-00 |
| filingDate |
2014-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb6d02a5cfba86b1d6e80e55eb236bd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7183035ae322d171ac979da7124f93a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_226363f457daaf93cf3c84e15d53a3ae |
| publicationDate |
2014-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014195734-A |
| titleOfInvention |
Biodegradable endoprosthesis and manufacturing method |
| abstract |
Medical devices and methods for their manufacture are provided. The biodegradable endoprosthesis is formed from an amorphous polymer having desirable biodegradable properties. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing biodegradation time. The crystallinity of the highly amorphous polymer is 10% or less before modification. After modification, the crystallinity is usually at least 20% of the original crystallinity of the amorphous material, preferably at least 100% of the original crystallinity of the amorphous material, more preferably non- Increased by at least 1000% of the original crystallinity of the crystalline material. Currently preferred polymeric materials have a crystallinity in the range of 10% to 20% after modification, as described herein. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190140321-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102328579-B1 |
| priorityDate |
2007-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |